| An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment X Tekpli, T Lien, AH Røssevold, D Nebdal, E Borgen, HO Ohnstad, ... Nature communications 10 (1), 5499, 2019 | 149 | 2019 |
| Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial AH Røssevold, NK Andresen, CA Bjerre, B Gilje, EH Jakobsen, SX Raj, ... Nature Medicine 28 (12), 2573-2583, 2022 | 33 | 2022 |
| ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer JA Kyte, A Røssevold, RS Falk, B Naume Journal of translational medicine 18, 1-7, 2020 | 18 | 2020 |
| 215MO ICON–a randomized phase IIb study evaluating chemotherapy combined with ipilimumab and nivolumab in metastatic hormone receptor-positive breast cancer JA Kyte, NK Andresen, C Quaghebeur, B Gilje, B Boge, A Gombos, ... Annals of Oncology 33, S636, 2022 | 3 | 2022 |
| Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation SK Chauhan, C Dunn, NK Andresen, AH Røssevold, G Skorstad, A Sike, ... NPJ Breast Cancer 10 (1), 30, 2024 | | 2024 |
| Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial NK Andresen, AH Røssevold, C Quaghebeur, B Gilje, B Boge, A Gombos, ... Journal for immunotherapy of cancer 12 (1), 2024 | | 2024 |
| Abstract PD11-11: PD11-11 Results from ALICE–Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple Negative Breast Cancer, a Randomized Phase … JA Kyte, AH Røssevold, NK Andresen, CA Bjerre, B Gilje, EH Jakobsen, ... Cancer Research 83 (5_Supplement), PD11-11-PD11-11, 2023 | | 2023 |
Jon Amund KyteOslo University hospitalVerified email at ous-hf.no
